Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

462 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index.
Goto H, Tsurumi H, Takemura M, Ino-Shimomura Y, Kasahara S, Sawada M, Yamada T, Hara T, Fukuno K, Goto N, Okuno M, Takami T, Seishima M, Moriwaki H. Goto H, et al. Among authors: seishima m. J Cancer Res Clin Oncol. 2005 Feb;131(2):73-9. doi: 10.1007/s00432-004-0600-9. Epub 2004 Oct 21. J Cancer Res Clin Oncol. 2005. PMID: 15503137
Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
Goto N, Tsurumi H, Takemura M, Hara T, Sawada M, Kasahara S, Kanemura N, Yamada T, Shimizu M, Takahashi T, Tomita E, Seishima M, Takami T, Moriwaki H. Goto N, et al. Among authors: seishima m. Eur J Haematol. 2006 Sep;77(3):217-25. doi: 10.1111/j.1600-0609.2006.00702.x. Epub 2006 Jul 19. Eur J Haematol. 2006. PMID: 16856931
Serum concentration of L-kynurenine predicts the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP.
Yoshikawa T, Hara T, Tsurumi H, Goto N, Hoshi M, Kitagawa J, Kanemura N, Kasahara S, Ito H, Takemura M, Saito K, Seishima M, Takami T, Moriwaki H. Yoshikawa T, et al. Among authors: seishima m. Eur J Haematol. 2010 Apr;84(4):304-9. doi: 10.1111/j.1600-0609.2009.01393.x. Epub 2009 Nov 7. Eur J Haematol. 2010. PMID: 19995374 Clinical Trial.
Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP.
Ninomiya S, Hara T, Tsurumi H, Hoshi M, Kanemura N, Goto N, Kasahara S, Shimizu M, Ito H, Saito K, Hirose Y, Yamada T, Takahashi T, Seishima M, Takami T, Moriwaki H. Ninomiya S, et al. Among authors: seishima m. Ann Hematol. 2011 Apr;90(4):409-16. doi: 10.1007/s00277-010-1093-z. Epub 2010 Oct 12. Ann Hematol. 2011. PMID: 20938662 Clinical Trial.
Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens.
Goto N, Tsurumi H, Kasahara S, Kanemura N, Hara T, Yasuda I, Shimizu M, Murakami N, Sawada M, Yamada T, Takemura M, Seishima M, Kito Y, Takami T, Moriwaki H. Goto N, et al. Among authors: seishima m. Eur J Haematol. 2011 Sep;87(3):217-27. doi: 10.1111/j.1600-0609.2011.01649.x. Epub 2011 Jul 26. Eur J Haematol. 2011. PMID: 21575062
Serum soluble CD27 level is associated with outcome in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone.
Goto N, Tsurumi H, Takemura M, Kanemura N, Kasahara S, Hara T, Yasuda I, Shimizu M, Yamada T, Sawada M, Takahashi T, Yamada T, Seishima M, Moriwaki H, Takami T. Goto N, et al. Among authors: seishima m. Leuk Lymphoma. 2012 Aug;53(8):1494-500. doi: 10.3109/10428194.2012.660627. Epub 2012 Mar 1. Leuk Lymphoma. 2012. PMID: 22280534
Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B-cell lymphoma treated with the R-CHOP regimen.
Nakamura N, Goto N, Tsurumi H, Takemura M, Kanemura N, Kasahara S, Hara T, Yasuda I, Shimizu M, Sawada M, Yamada T, Seishima M, Takami T, Moriwaki H. Nakamura N, et al. Among authors: seishima m. Eur J Haematol. 2013 Oct;91(4):322-31. doi: 10.1111/ejh.12139. Epub 2013 Jul 7. Eur J Haematol. 2013. PMID: 23672298
Serum soluble tumor necrosis factor receptor 1 level is associated with the outcome of diffuse large B-cell lymphoma patients treated with the CHOP or R-CHOP regimen.
Goto N, Tsurumi H, Takemura M, Matsumoto T, Shibata Y, Mabuchi R, Nakamura N, Nakamura H, Yamada T, Seishima M, Takami T, Takeuchi T, Moriwaki H. Goto N, et al. Among authors: seishima m. J Clin Exp Hematop. 2014;54(2):117-27. doi: 10.3960/jslrt.54.117. J Clin Exp Hematop. 2014. PMID: 25318944 Free article. No abstract available.
Serum concentrations of l-kynurenine predict clinical outcomes of patients with peripheral T-cell lymphoma, not otherwise specified.
Shibata Y, Hara T, Matsumoto T, Nakamura N, Nakamura H, Ninomiya S, Kitagawa J, Goto N, Nannya Y, Ito H, Kito Y, Miyazaki T, Takeuchi T, Saito K, Seishima M, Takami T, Moriwaki H, Shimizu M, Tsurumi H. Shibata Y, et al. Among authors: seishima m. Hematol Oncol. 2017 Dec;35(4):637-644. doi: 10.1002/hon.2318. Epub 2016 Jun 24. Hematol Oncol. 2017. PMID: 27338762
[Soluble tumor necrosis factor receptor I, II].
Takemura M, Saito K, Seishima M. Takemura M, et al. Among authors: seishima m. Nihon Rinsho. 2005 Aug;63 Suppl 8:158-60. Nihon Rinsho. 2005. PMID: 16149477 Review. Japanese. No abstract available.
462 results